Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

BACKGROUND: The undetermined efficacy of the current standard-of-care neoadjuvant treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple-negative breast cancer (TNBC) and germline BRCA mutations emphasizes the need for biomarker-targeted treatment, such as poly(ADP...

Descripción completa

Detalles Bibliográficos
Autores principales: Litton, Jennifer K, Beck, J Thaddeus, Jones, Jason M, Andersen, Jay, Blum, Joanne L, Mina, Lida A, Brig, Raymond, Danso, Michael, Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Niyazov, Alexander, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William F, Telli, Melinda L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546823/
https://www.ncbi.nlm.nih.gov/pubmed/37318349
http://dx.doi.org/10.1093/oncolo/oyad139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546823/
https://www.ncbi.nlm.nih.gov/pubmed/37318349
http://dx.doi.org/10.1093/oncolo/oyad139

Ejemplares similares